凯杰

🎉 We’re excited to announce U.S. clearance for the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, tailored to provide rapid answers for outpatient diagnosis of gastrointestinal conditions. Learn more 👉 https://lnkd.in/ezUjEmFd ✅ The new panel detects five common bacterial and viral pathogens causing gastrointestinal infections to support year-round outpatient care with fast and accurate results. ✅ We are the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients. 🚀 The QIAstat-Dx Rise, a higher-capacity instrument version, will be submitted for U.S. regulatory clearance in early 2025, following the success of four QIAstat-Dx Panel clearances in 2024.

If you want to make your lab work more productive and cost-efficient, we have good news for you! QIAcuity dPCR now supports high-order multiplexing capabilities without requiring instrument hardware changes, enabling deeper insights from biological samples. Learn more 👉 https://lnkd.in/eUS973DC ✅ Detect up to 12 targets simultaneously from a single biological sample – a more than two-fold increase from the previous limit of five targets. ✅ The new QIAcuity Software 3.1 update and the QIAcuity High Multiplex Probe PCR Kit enable this capability with no hardware changes required. ✅ Save time, reduce reagent consumption, and optimize the use of precious sample materials for more productive and cost-efficient lab work.

🎉 We are proud to support the British National Health Service (NHS) and Genomics England with our Clinical Knowledge Base to power a first-of-its-kind whole-genome sequencing study for newborns. Learn more 👉 https://lnkd.in/eZrjK5E8 ✅ This initiative aims to sequence the genomes of 100,000 newborns in the United Kingdom (UK) to screen for over 200 selected conditions, enabling earlier diagnosis and treatment. ✅ Our clinically relevant variant content will be available at testing sites across the UK to support evidence-based variant interpretation and result reporting. ✅ Partnering with Genomics England in this landmark program allows us to provide nationwide access to the power of whole-genome sequencing for newborns in the UK, with the potential to improve the health of thousands of families.

🙌 We're proud to announce that QIAGEN has once again achieved a perfect 💯 in the Human Rights Campaign Foundation’s 2025 Corporate Equality Index (CEI)! 🌍 This recognition underscores our unwavering commitment to fostering an inclusive workplace where LGBTQ+ equality thrives. The CEI primarily evaluates U.S. companies on comprehensive non-discrimination policies, equitable benefits, inclusive culture initiatives, and public commitment to LGBTQ+ equality. 👏 A huge thank you to all QIAGENers—across every level and role—for creating a workplace where everyone feels valued, respected, and empowered to succeed. Together, we’re building a better future for all.

🙏 As we reflect on 2024, we want to take a moment to extend our heartfelt gratitude to everyone who has been part of our journey – our dedicated employees, loyal customers, and amazing partners. 🌟 Your passion and commitment have been the driving force behind our mission to make improvements in life possible in a year filled with challenges and opportunities alike. 🎉 Here’s to celebrating your unwavering support and partnership. We wish you a wonderful holiday season and a bright, successful New Year ahead!

🌍 Taking action on renewable energy isn’t just about numbers—it’s about making a tangible difference for the environment and future generations. ✅ At QIAGEN, we’ve made progress by transitioning to renewable energy at our Germantown and Hilden sites, contributing to 84% green electricity across all our locations—and this is just the beginning! ✅ Looking ahead to 2025, we will continue our green electricity sourcing strategy while focusing on energy efficiency gains to maximize our impact. This is part of our commitment to achieving our goal of a validated net-zero carbon footprint by 2050. 💡 Want to learn more about sustainability at QIAGEN? Check out our new sustainability webpage, where we share all the details about our ongoing efforts to protect the planet. 👉 https://lnkd.in/eGuzese

We are excited to announce the launch of our Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Learn more 👉 https://lnkd.in/eW3b5rAb ✅ Our Ingenuity Pathway Analysis Interpret extends the analysis capabilities of a human-curated knowledge base with AI technology. ✅ This AI extension highlights key biological elements at work and provides summarized results and interpretations in a shareable web document, speeding up the interpretation process. ✅ Ingenuity Pathway Analysis Interpret is the key to unlocking the full potential of biological data by streamlining the interpretation process and delivering actionable insights for experiments.

Get great results while lessen pipetting, lower energy usage and increase efficiency 🧪. Join now and in 20 minutes: ✅ Unbox the leaner, greener QIAwave kit. Get more out of #DNA and #RNA isolations while taking out the trash less often. ✅ Reduce RNA-seq pipetting by >80%. Stop pipetting box after box of filter tips. Get the same diversity of results with 11 fewer boxes of filter tips per 192 reactions. ✅ Save space in your –20? Learn tricks and tips on how you can reduce your cold storage and lab's energy use.

Every day, meningitis changes lives – and claims lives – in every part of the world. But you have the power to change that. You can fight back by better knowing your enemy. And we want to help. That's why we've created an online education program that summarizes the latest trends in meningitis epidemiology and diagnostics. Visit the education hub now to get: ✅ Ebook guide to emerging issues in pediatric meningitis/encephalitis ✅ On-demand webinars from experts working in the clinic and lab ✅ Detailed clinical case studies You can lessen the burden of meningitis in your community. One lesson at a time. Start learning 👉 https://lnkd.in/edDZtBwV

🎉 Exciting news! Our EZ2 Connect has reached a significant milestone with over 1,000 placements worldwide, contributing to a global installed base of more than 5,500 EZ series instruments! Learn more 👉 https://lnkd.in/gWmby7-t ✅ The comprehensive portfolio of EZ2 Connect automated kits provides research and clinical labs with more time for in-depth analyses, reducing the need for manual processing. ✅ We recently launched the EZ2 PowerFecal Pro DNA/RNA Kit, expanding the portfolio into gut microbiome research. This builds on the EZ2 Connect kits for applications such as diagnostics, genomics and cancer research, molecular epidemiology, and forensics.